Several manufacturers are bypassing established HRSA guidance and placing restrictions on 340B drug access. Learn more about this pattern of interference.

On May 17, 2021, HRSA informed pharmaceutical manufacturers AstraZeneca, Eli Lilly, Novartis, Novo Nordisk, Sanofi and United Therapeutics that their restrictions on 340B pricing to covered entities that dispense medications through contract pharmacies have resulted in overcharges and are in direct violation of the 340B statute.

The 340B world received a big dose of good news this week when the Health Resources and Services Administration (HRSA) notified six drug manufacturers that their practice of not extending 340B pricing to contract pharmacies was in violation of the statute.

In his best-selling book, Good to Great, Jim Collins describes the Flywheel Effect as the constant, sustained energy necessary to create the momentum behind any great change or undertaking.

Sentry webinars supplement our robust one to one instructor led training curriculum and provide timely updates on what’s happening in 340B.

What happens after contracting with a specialty pharmacy? Read this post to learn more.

This 340Buzz article will cover the American Rescue Plan Act of 2021, Xavier Becerra becoming Secretary of Health and Human Services and more.

Aside from the benefits of contracting with a specialty pharmacy, covered entities should understand the business models of these pharmacies in order to negotiate a contract that will be beneficial to them. Read on to learn about dispensing fee models for specialty pharmacies.

How can a specialty pharmacy substantially maximize your 340B benefits?